Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 July 2025 | Story Tshepo Tsotetsi | Photo Supplied
Prof Ivan Turok
Prof Ivan Turok has been awarded the Distinguished Service Award for 2025 by the Regional Studies Association.

Prof Ivan Turok, who holds the National Research Foundation (NRF) Chair in City-Region Economies in the Department of Economics and Finance in the Faculty of Economic and Management Sciences at the University of the Free State (UFS), has been named a recipient of the 2025 Distinguished Service Award by the Regional Studies Association (RSA)

This international recognition celebrates Prof Turok’s significant contribution to the field of urban and regional research, both globally and on the African continent.

A longstanding member of the RSA, Prof Turok has served as Editor-in-Chief of Regional Studies and as Editor of Area Development and Policy, two of the Association’s six academic journals. He also served on the RSA Board between 2014 and 2018. The RSA is a UK-based learned society and the foremost global forum for city and regional research, development and policy. It manages six international journals, two book series, and hosts several international conferences annually. The award highlights not only his leadership in global academic spaces but also his efforts in representing scholarship from the global South.

“This recognition is a testament to the calibre of scholars within the EMS Faculty and thus significantly enhances the faculty’s research profile and global reputation,” said Prof Brownhilder Neneh, Vice-Dean for Research, Engagement and Internationalisation in the Faculty of Economic and Management Sciences.

 

Championing urban development in Africa

Prof Turok’s research has focused on the economic structure and performance of cities in South Africa and across the continent. He has analysed the obstacles to faster economic growth and development and the key interventions required to support accelerated investment and job creation. These include public infrastructure investment and improved land-use management to create more functional, efficient cities.

With over 150 academic journal articles and 15 books and monographs to his name, Prof Turok is one of the most highly cited urban and regional development scholars in the world.

“Receiving the Distinguished Service Award is a great honour, particularly in representing academics from the global South,” he said. “Africa faces unprecedented challenges in managing rapid urbanisation, but also unique opportunities for cities to transform its development trajectory. More research is vital to inform the tough policy choices facing governments.”

He believes cities are “remarkable vehicles” for accelerated growth and inclusive development. “The concentration of human, private and public capital generates positive value and fosters learning, creativity, and innovation,” he added.

Improved evidence and understanding of urban economic systems and dynamics, he argues, are essential for harnessing the youthful energy of African cities. “Universities have a vital role to play in generating the knowledge, capabilities, and strategic intelligence required by governments, civil society, business, and communities to make African cities and regions more prosperous, inclusive, and resilient.” 

Prof Neneh said the award reconfirms Prof Turok’s global standing in regional and urban economics. “He fills a significant gap by applying spatial economics to urban and regional development in an integrated manner – this is especially of value in Africa, where it has been neglected.”

Prof Turok encourages young scholars to explore opportunities offered by the RSA, describing it as a welcoming and dynamic space to learn, connect, and grow. “It is a very friendly and supportive forum, with various special schemes and grants to help young scholars participate in conferences, publish in journals, and learn from each other.” 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept